The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10439 malaria professionals are enjoying the free benefits of MalariaWorld today

artesunate

Open Access | A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania

August 30, 2011 - 10:07 -- Kabogo Ndegwa
Author(s): 
Shekalaghe SA, Drakeley C, van den Bosch S, ter Braak R, van den Bijllaardt W, Mwanziva C, Semvua S, Masokoto A, Mosha F, Teelen K, Hermsen R, Okell L, Gosling R, Sauerwein R, Bousema T
Reference: 
Malaria Journal 2011, 10:247 (24 August 2011)

This study illustrates the possibility to achieve high coverage with a three-day intervention but also the difficulty in defining suitable outcome measures to evaluate interventions in areas of very low malaria transmission intensity.

Country: 
Medical Condition: 
Medical Treatment: 

Pharmacokinetics and Ex Vivo Antimalarial Activity of Artesunate-Azithromycin in Healthy Volunteers

August 18, 2011 - 14:58 -- Patrick Sampao
Author(s): 
Nguyen Trong Chinh, Nguyen Ngoc Quang, Michael D. Edstein, et al.
Reference: 
Antimicrobial Agents and Chemotherapy, September 2011,p. 4412-4415, Vol. 55, No. 9

In 18 male healthy subjects, artesunate (200 mg)-azithromycin (1,500 mg) daily for 3 days was found to be well tolerated, with only mild gastrointestinal disturbances reported.

Technology: 
Product: 
Person: 
Medical Treatment: 

Open Access | Methodology: Pre-referral rectal artesunate in severe malaria: a flawed trial

August 11, 2011 - 07:39 -- Patrick Sampao
Author(s): 
Karim F Hirji and Zulfiqarali G Premji
Reference: 
Trials 2011, 12:188

We performed a checklist-based and an in-depth evaluation of the trial. The evaluation criteria were based on the CONSORT statement for reporting clinical trials, the clinical trial methodology literature, and practice in malaria research.

Medical Condition: 
Medical Treatment: 

Open Access | Plasmodium falciparum isolates from southern Ghana exhibit polymorphisms in the SERCA-type PfATPase6 though sensitive to artesunate in vitro

July 12, 2011 - 07:53 -- Kabogo Ndegwa
Author(s): 
Kwansa-Bentum B, Ayi I, Suzuki T, Otchere J, Kumagai T, Anyan WK, Osei JH, Asahi H, Ofori MF, Akao N, Wilson MD, Boakye DA, Ohta N
Reference: 
Malaria Journal 2011, 10:187 (11 July 2011)

The pfATPase6 gene is highly polymorphic with D639G appearing to be fixed in Ghanaian isolates.

Organization: 
Country: 
Medical Condition: 
Medical Treatment: 

Open Access | Artesunate Dose Escalation for the Treatment of Uncomplicated Malaria in a Region of Reported Artemisinin Resistance: A Randomized Clinical Trial

May 30, 2011 - 08:28 -- Kabogo Ndegwa
Author(s): 
Delia Bethell, Youry Se, Mark M. Fukuda, et al.
Reference: 
PLoS ONE 6(5): e19283

There is no pharmacodynamic benefit of increasing the daily dose of AS (4mg/kg) currently recommended for short-course combination treatment of uncomplicated malaria, even in regions with emerging artemisinin resistance, as long as the partner drug retains high efficacy.

Medical Treatment: 

Open Access | Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with malaria

May 10, 2011 - 08:09 -- Kabogo Ndegwa
Author(s): 
Carrie A Morris, Marie A Onyamboko, Edmund Capparelli, Matthew A Koch, Joseph Atibu, Vicky Lokomba, Macaya Douoguih, Jennifer Hemingway-Foday, David Wesche, Robert W Ryder, Carl Bose, Linda Wright, Antoinette K Tshefu, Steven Meshnick, Lawrence Fleckenstein
Reference: 
Malaria Journal 2011, 10:114 (8 May 2011)

In this analysis, pharmacokinetic modelling suggests that pregnant women have accelerated DHA clearance compared to non-pregnant women receiving orally administered AS.

Person: 
Medical Condition: 
Medical Treatment: 

Open Access | In vitro and in vivo assessment of the anti-malarial activity of Caesalpinia pluviosa and analysis of its active fractions

May 5, 2011 - 08:23 -- Kabogo Ndegwa
Author(s): 
Ana Carolina AV Kayano, Stefanie CP Lopes, Fernanda G Bueno, Elaine C Cabral, Wanessa CS Neiras, Lucy M Yamauchi, Mary A Foglio, Marcos N Eberlin, Joao Carlos P Mello, Fabio T Costa
Reference: 
Malaria Journal 2011, 10:112 (2 May 2011)

The findings show that the F4 fraction of C. pluviosa exhibits anti-malarial activity in vitro at non-toxic concentrations, which was potentiated in the presence of artesunate.

Medical Treatment: 

Open Access | Artesunate versus quinine for treating severe malaria

April 5, 2011 - 09:26 -- Kabogo Ndegwa
Author(s): 
David Sinclair, Sarah Donegan, David G Lalloo
Reference: 
Cochrane Infectious Diseases Group, Issue 3, 2011

Two authors independently assessed the eligibility and risk of bias of trials, and extracted and analysed data.

Medical Condition: 
Medical Treatment: 

Open Access | Commentary: Intermittent preventive therapy for malaria: arguments in favour of artesunate and sulphamethoxypyrazine - pyrimethamine combination

March 31, 2011 - 07:34 -- Kabogo Ndegwa
Author(s): 
Jansen F
Reference: 
Malaria Journal 2011, 10:70 (29 March 2011)

Recent publications put a serious warning regarding the inefficacy of sulphadoxine-pyrimethamine (SP) for the intermittent preventive treatment of malaria in young children (IPTi).

Medical Condition: 

Artemether and Artesunate Show the Highest Efficacies in Rescuing Mice with Late-Stage Cerebral Malaria and Rapidly Decrease Leukocyte Accumulation in the Brain

March 22, 2011 - 11:55 -- Kabogo Ndegwa
Author(s): 
L. Clemmer, Y. C. Martins, G. M. Zanini, J. A. Frangos, and L. J. M. Carvalho
Reference: 
Antimicrobial Agents and Chemotherapy, April 2011, p. 1383-1390, Vol. 55, No. 4

The murine model of cerebral malaria (ECM) caused by Plasmodium berghei ANKA (PbA) infection in susceptible mice has been extensively used for studies of pathogenesis and identification of potential targets for human CM therapeutics.

Medical Condition: 
Medical Treatment: 

Pages

Subscribe to RSS - artesunate